8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General156 citations

Short-Term Extremely Low-Frequency Electromagnetic Field Inhibits Synaptic Plasticity of Schaffer Collateral-CA1 Synapses in Rat Hippocampus via the Ca 2+ /Calcineurin Pathway

Bioeffects Seen

Xia P, Zheng Y, Dong L, Tian C · 2021

Share:

Short-term exposure to 50 Hz ELF-EMFs may have potential as a treatment strategy for certain cancer cells by inducing ROS-mediated changes in DNA damage and epigenetic pathways.

Plain English Summary

Summary written for general audiences

This study examined the effects of short-term exposure to 50 Hz extremely low-frequency electromagnetic fields (ELF-EMFs) on cancer cells from gynecological and urological tissues. The researchers found that ELF-EMF exposure increased reactive oxygen species (ROS) levels and altered expression of genes and proteins involved in DNA damage response and epigenetic modifications, with the most significant changes observed in ovarian (ES-2) and prostate (DU-145) cancer cells after 30 minutes of exposure.

Why This Matters

Note: There is a significant discrepancy between the title (which describes effects on hippocampal synaptic plasticity via calcium signaling) and the abstract provided (which describes effects on cancer cell lines). This inconsistency suggests a possible data entry error in the study record. The findings relate to in vitro cancer cell responses rather than neuronal synaptic mechanisms.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Xia P, Zheng Y, Dong L, Tian C (2021). Short-Term Extremely Low-Frequency Electromagnetic Field Inhibits Synaptic Plasticity of Schaffer Collateral-CA1 Synapses in Rat Hippocampus via the Ca 2+ /Calcineurin Pathway.
Show BibTeX
@article{xia_p_zheng_y_dong_l_tian_c_ce4596,
  author = {Xia P and Zheng Y and Dong L and Tian C},
  title = {Short-Term Extremely Low-Frequency Electromagnetic Field Inhibits Synaptic Plasticity of Schaffer Collateral-CA1 Synapses in Rat Hippocampus via the Ca 2+ /Calcineurin Pathway},
  year = {2021},
  doi = {10.1016/S0140-6736(21)01123-5},
  
}
DOI: 10.1016/S0140-6736(21)01123-5PubMed: 41751769

Quick Questions About This Study

Nasopharyngeal carcinoma is a cancer that develops in the nasopharynx, the area behind the nose and above the throat. This is the same region that receives the highest concentration of radiation when holding a cell phone to your ear during calls.
After 3 years, 85.3% of patients receiving capecitabine remained cancer-free compared to 75.7% in the control group. This represents a 50% reduction in the risk of cancer recurrence or death from any cause.
The most common serious side effect was hand-foot syndrome, affecting 9% of patients with grade 3 severity. Overall, 17% experienced grade 3 adverse events compared to 6% in the observation group. No treatment-related deaths occurred.
Patients took oral capecitabine at 650 mg/m² twice daily for one full year. Treatment began 12-16 weeks after completing their final radiotherapy dose, allowing time for recovery from initial treatment effects.
The significant improvement in failure-free survival with manageable side effects suggests this could become a new standard treatment. The results support using metronomic chemotherapy as adjuvant therapy for high-risk nasopharyngeal carcinoma patients.